Medincell SA (MEDCL) - Total Assets
Based on the latest financial reports, Medincell SA (MEDCL) holds total assets worth €108.05 Million EUR (≈ $126.33 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medincell SA - Total Assets Trend (2016–2026)
This chart illustrates how Medincell SA's total assets have evolved over time, based on quarterly financial data. Also see MEDCL stock market capitalisation for the company's overall valuation and market capitalisation.
Medincell SA - Asset Composition Analysis
Current Asset Composition (March 2026)
Medincell SA's total assets of €108.05 Million consist of 89.5% current assets and 10.5% non-current assets. Review MEDCL total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 58.1% |
| Accounts Receivable | €4.51 Million | 4.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.48 Million | 3.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2026)
This chart illustrates how Medincell SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Medincell SA stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medincell SA's current assets represent 89.5% of total assets in 2026, an increase from 63.7% in 2016.
- Cash Position: Cash and equivalents constituted 58.1% of total assets in 2026, up from 5.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 11.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 4.2% of total assets.
Medincell SA Competitors by Total Assets
Key competitors of Medincell SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Medincell SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.67 | 2.70 | 4.14 |
| Quick Ratio | 4.67 | 2.70 | 4.01 |
| Cash Ratio | 0.00 | 1.37 | 0.22 |
| Working Capital | €76.02 Million | €50.74 Million | €42.73 Million |
Medincell SA - Advanced Valuation Insights
This section examines the relationship between Medincell SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 264.87 |
| Latest Market Cap to Assets Ratio | 7.32 |
| Asset Growth Rate (YoY) | 19.5% |
| Total Assets | €108.05 Million |
| Market Capitalization | $790.73 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Medincell SA's assets at a significant premium (7.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Medincell SA's assets grew by 19.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Medincell SA (2016–2026)
The table below shows the annual total assets of Medincell SA from 2016 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | €108.05 Million ≈ $126.33 Million |
+19.46% |
| 2025-03-31 | €90.45 Million ≈ $105.75 Million |
+144.81% |
| 2024-03-31 | €36.95 Million ≈ $43.20 Million |
+25.93% |
| 2023-03-31 | €29.34 Million ≈ $34.30 Million |
-33.78% |
| 2022-03-31 | €44.30 Million ≈ $51.79 Million |
-30.35% |
| 2021-03-31 | €63.61 Million ≈ $74.36 Million |
+132.93% |
| 2020-03-31 | €27.31 Million ≈ $31.92 Million |
-28.11% |
| 2019-03-31 | €37.98 Million ≈ $44.40 Million |
+49.81% |
| 2018-03-31 | €25.35 Million ≈ $29.64 Million |
+8.97% |
| 2017-03-31 | €23.27 Million ≈ $27.20 Million |
+108.24% |
| 2016-03-31 | €11.17 Million ≈ $13.06 Million |
-- |
About Medincell SA
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment … Read more